Clinical Highlights

Wish to hear experienced clinicians provide guidance on osteoporosis diagnosis and treatment?
The ECTS Clinical Update Program on Saturday morning is the place to be. Topics include:

  • Osteoporosis – diagnostic workup
  • Fracture risk assessment and intervention thresholds
  • Calcium and vitamin D
  • Choice of treatment
  • Treatment of osteoporosis in patients with reduced kidney function

 

Are you interested in disorders affecting bone beyond osteoporosis?
At ECTS 2017 we will focus on endocrinological disorders and bone with overview lectures by top opinion leaders. Topics include:

  • Diabetes and bone health
  • Thyroid diseases and bone health
  • Sodium and bone health
  • Parathyroid diseases and bone health

 

What is new in clinical bone research?

  • Listen to What is New – The Year in Review to get an overview of major innovations of the past year presented by one of the top opinion leaders.

 

New bone anabolic treatments may soon become available – should you fundamentally change your approach to treat osteoporosis?
Listen to the clinical debate on

  • “This house believes that anabolic therapy should be first line therapy for patients with established osteoporosis”

 

Wish to hear the latest state of the art clinical research ?
ECTS 2017 has experts from around the world covering the topics in different presentation formats:

  • Plenary lecture Insights from Outside.
  • This year the topic is Big Data. How can data mining affect diagnosis and treatment in the future?

 

Clinical workshops

  • Bone in rheumatoid disorders
  • Nutrition and bone
  • Vitamin D, back to the future

 

Symposia

  • Fracture risk in neurological diseases
  • BMD revisited: Can BMD be used as a surrogate for fracture risk reduction?
  • Tendon injury and therapy

 

Meet the Experts

  • Dennis Black: Long-term treatment of osteoporosis
  • Terry Aspray: Optimal replacement with vitamin D
  • Jenny Walsh: How to manage the young person with osteoporosis
  • Ken Saag: Difficult cases in glucocorticoid-induced osteoporosis

and, as a special topic:

Randy Levinson: How to publish in Nature Medicine

 

Working Groups

  • Rheumatologic disorders of bone
  • Imaging of bone strength
  • Rare bone diseases (NEW)

ECTS

ECTS

The European Calcified Tissue Society (ECTS) is the major organisation in Europe for researchers and clinicians working in the field of calcified tissues and related fields. For over 50 years the Society has acted as a forum to promote the highest levels of knowledge, research and education through its annual meetings, training courses and grants and awards. Membership of the ECTS is open to anyone working in the field at whatever stage in their career. Come and meet us in Salzburg at stand numbers 1, 2, 3. www.ectsoc.org

Stratec Medizintechnik

web-stragalStratec Medizintechnik is the world’s most successful producer of pQCT-based bone densitometry scanners. Results are presented in real density units (g/cm³). Additionally geometrical properties of bone can be analysed which allow the estimation of mechanical properties. The combined analysis of muscle and bone allows differentiation of disuse osteopenia from true osteoporosis.

The sister company Novotec Medical is manufacturer of Galileo vibration training devices for muscle stimulation and of Leonardo motion analysis systems (mechanography). The side alternating technology employs a natural movement similar to human gait. Improvement of muscle function, treatment of back pain and immobility are typical fields of application.

Kyowa Hakko Kirin

xhl_corporate_logo_vertical_k_rgbKyowa Hakko Kirin (KHK) is a biopharmaceutical company focusing on its core business area of oncology, nephrology, and immunology/allergy. KHK discovered KRN23, an investigational fully human monoclonal antibody administered via subcutaneous injection designed to bind and thereby reduce the excess biological activity of FGF23. KHK formed a collaboration with Ultragenyx to jointly develop KRN23 for the treatment of X-Linked Hypophosphatemia (XLH), a rare genetic metabolic bone disease, and Tumor- Induced Osteomalacia (TIO). Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

Faxitron

1006-3-faxitron-logoFaxitron is the pioneer and continues to be the most used brand in cabinet X-ray. Faxitron offers compact digital imaging and pre-clinical DEXA systems with the highest resolution (< 10µm) and the largest field of view in the market. These systems are less expensive, expose animals to lower doses, and offer faster results than microCT or 3D systems. Faxitron cabinets can be placed directly in the animal facility or surgical suite with no other shielding required.

Amgen

amgenlogo_blue_rgb_withouttagAmgen is committed to unlocking the potential of biology for patients suffering from
serious illnesses by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like advanced human genetics
to unravel the complexities of disease and understand the fundamentals of human
biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive
for solutions that improve health outcomes and dramatically improve people’s lives. A
biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading
independent biotechnology companies, has reached millions of patients around the world
and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Alexion

web_corporate-logo-rgb

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies – Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D). Alexion also developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion is advancing the most robust rare disease pipeline in the biotech industry with highly innovative product candidates in multiple therapeutic areas. www.alexion.com

Sponsors & Exhibitors

as of December 11, 2016

Confirmed Sponsors

 

Gold Sponsors

 web_corporate-logo-rgb amgenlogo_blue_rgb_withouttag jpg_ucb_logo_reflex_rgb

Sponsors

 

Pre-congress Sponsors

Confirmed Exhibitors

Exhibitor Exhibition Space
Aginko 14
web_corporate-logo-rgb Alexion 4, 5
amgenlogo_blue_rgb_withouttag Amgen 6, 7, 8
  Biomedica 9a
  Bruker 10
ECTS ECTS 1, 2, 3
1006-3-faxitron-logo Faxitron 13
  IDS 15
xhl_corporate_logo_horizontal_k_rgb Kyowa Hakko Kirin 11
Medi Manage Innovation 17
Perkin Elmer 16
PolyGene 9b
SCANCO Medical 18
web-stragal Stratec Medizintechnik 12

 

Klick on the image below to open the interactive floor plan.

1 2 3 4 5